Artelo Biosciences (ARTL) vs Scinai Immunotherapeutics (SCNI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Artelo Biosciences is the larger company by market cap ($1.8 million vs $1.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTL | SCNI |
|---|---|---|
| Share price | $3.26 | $1.19 |
| Market cap | $1.78M | $1.61M |
| 1-day change | -3.41% | -1.65% |
| P/E ratio (TTM) | — | 0.04 |
| EPS (TTM) | $-136.26 | $28.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $179.19 | $15.65 |
| 52-week low | $3.23 | $1.06 |
| Distance from 52-week high | -98.18% | -92.40% |
| Average volume | 480.92K | 1.10M |
| Shares outstanding | 547.77K | 1.35M |
| Employees | 7 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Artelo Biosciences
ARTL stock →Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Scinai Immunotherapeutics
SCNI stock →Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
ARTL vs SCNI FAQ
Which is bigger, Artelo Biosciences or Scinai Immunotherapeutics?
Artelo Biosciences (ARTL) is larger, with a market capitalization of $1.78M compared with $1.61M for Scinai Immunotherapeutics (SCNI).
Are Artelo Biosciences and Scinai Immunotherapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Artelo Biosciences and Biotechnology: Biological Products (No Diagnostic Substances) for Scinai Immunotherapeutics.